Home | KUP | Dr. Endege Kicks off Biotech Company to Implement KUP-Biotechnology Plan

Dr. Endege Kicks off Biotech Company to Implement KUP-Biotechnology Plan

Font size: Decrease font Enlarge font
Dr. Wilson Endege signs and files resolution to start Biotechnology Company at Attorney Kamau offices in Worcester, MA Dr. Wilson Endege signs and files resolution to start Biotechnology Company at Attorney Kamau offices in Worcester, MA

Dr. Wilson Endege, a Research Scientist who has been in the Biotechnology sector and has 5 patents in the field of cancer treatment, kicked off the Biotech Company that will implement the Kenya University Project KUP - Biotechnology Plan with a resolution filed at Attorney Njoroge law firm in Worcester. The Biotechnology plan is a plan to produce 23 Medicines and Vaccines as well as diagnostic reagents for the African market. The company production facility will be located at the University Town.

Attorney Njoroge Kamau was happy to open the file that the resolution will be implemented through as capital flows into the Company as planned. He thanked Dr. Endege for his commitment to expand the healthcare sector in Kenya pointing out that the research and development of medicine and vaccines will benefit many Kenyans.   

Dr. Endege on his part noted that the Global Biologics Medicine and Vaccine production and consumption is a $300 billion economy. The 100 countries with life expectancy of over 75 years are estimated to produce and consume 80% of this $300 billion economy. He said, “Kenya and Africa countries, with a lower than 75 years life expectancy, do not have a fully developed Medicine and Vaccine economy.” 

It is this economy that the KUP-Biotechnology Plan implemented through be Biotech Company will advance. The plan will enable Kenyans invest in this sector that is projected to be the fastest growing economic sector as the world population increases from the current 7.5 billion persons to 10 billion persons. The medicine and vaccine global economy is expected to double to $600 billion. 

KUP developers investing in the company forecast that once the biotechnology company is up and running it will be one of the fastest growing companies in Kenya. Based on the new technology that Dr. Endege has been working on the last two years, the company target is to have a medicine and vaccines market share of $10 billion in production and sales for the Africa market as the global economy doubles.      

Dr. Endege who spent several years at Harvard University adds that the primary goals of the biotechnology plan are: to advance research and innovation on diseases as the biotechnology plan is implemented by the Biotechnology Company and University; creation of new jobs in Kenya and expansion of Kenya GDP; and the attainment of the right of healthcare as provided in Kenya constitution 43 (1) Every person has the right— (a) to the highest attainable standard of health, which includes the right to health care services, including reproductive health care, and 43 (2) A person shall not be denied emergency medical treatment.

DUT
  • email Email to a friend
  • print Print version
  • Plain text Plain text
Tags
No tags for this article
Rate this article
0